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The roles of extracellular residues of G-protein-coupled
receptors (GPCRs) are not well defined compared with residues
in transmembrane helices. Nevertheless, it has been established
that extracellular domains of both peptide-GPCRs and amine-
GPCRs incorporate functionally important residues. Extracel-
lular loop 2 (ECL2) has attracted particular interest, because the
x-ray structure of bovine rhodopsin revealed that ECL2 projects
into the binding crevice within the transmembrane bundle. Our
study provides the first comprehensive investigation into the
role of the individual residues comprising the entire ECL2
domain of a small peptide-GPCR. Using the V1a vasopressin
receptor, systematic substitution of all of the ECL2 residues by
Ala generated 30 mutant receptors that were characterized
pharmacologically. The majority of these mutant receptor con-
structs (24 in total) had essentially wild-type ligand binding and
intracellular signaling characteristics, indicating that these res-
idues are not critical for normal receptor function. However,
four aromatic residues Phe189, Trp206, Phe209, and Tyr218 are
important for agonist binding and receptor activation and are
highly conserved throughout the neurohypophysial hormone
subfamily of peptide-GPCRs. Located in the middle of ECL2,
juxtaposed to the highly conserved disulfide bond, Trp206 and
Phe209 project into the binding crevice. Indeed, Phe209 is part
of the Cys-X-X-X-Ar (where Ar is an aromatic residue) motif,
which is well conserved in both peptide-GPCRs and amine-
GPCRs. In contrast, Phe189 and Tyr218, located at the extreme
ends of ECL2, may be important for determining the position
of the ECL2 cap over the binding crevice. This study provides
mechanistic insight into the roles of highly conserved ECL2
residues.
G-protein-coupled receptors (GPCRs)5 exhibit a common
tertiary structure comprising seven transmembrane helices
(TMs) linked by extracellular loops (ECLs) and intracellular
loops. The atomic detail of this generic GPCR protein fold has
been reported for bovine rhodopsin (bRho). This confirmed
that the chromophore 11-cis-retinal is covalently linked to
TMVII and projects into a binding pocket formed within the
TM bundle where it interacts with amino acid side chains and
water molecules (1, 2). Likewise, the binding pocket for small
biogenic amine neurotransmitters such as acetylcholine and
norepinephrine is buried deep within the TM bundle (3).
Despite this buried location of the ligand binding site, the exo-
facial domains of bRho are highly structured and interact with
each other andwith theTMhelices. In particular, ECL2of bRho
forms a twisted -hairpin structure that plunges down into the
TMhelical bundle to form a plug over the chromophore. There
is also evidence that this ECL2 fold is not restricted to bRho and
occurs in other GPCRs (4). In addition, the orientation of ECL2
in the majority of GPCRs is restrained by a conserved disulfide
bond between ECL2 and the top of TMIII (1, 2).
The neurohypophysial peptide hormones vasopressin (AVP)
and oxytocin (OT) are structurally related nonapeptides that
generate a wide range of physiological effects, including vaso-
pressor, antidiuretic, and uterotonic actions (5, 6). The effects
of AVP/OT are mediated by a family of receptors (V1aR, V1bR,
V2R, and OTR), which, together with the receptors for vasoto-
cin, mesotocin, and isotocin from lower vertebrates, constitute
a sub-family of the rhodopsin/-adrenergic receptor class of
GPCRs (Family A). TheV1aR is widely distributed andmediates
nearly all of the actions of AVP with the exceptions of antidi-
uresis (V2R) and ACTH secretion (V1bR). Activation of the
OTR stimulates contraction of the uterinemyometrium during
labor and mammary myoepithelium to elicit lactation. The
V1aR, V1bR, and OTR couple to phospholipase C thereby gen-
erating inositol 1,4,5-trisphosphate and diacylglycerol as sec-
ond messengers, whereas the V2R stimulates adenylyl cyclase.
In addition to the characteristic architecture of GPCRs, mem-
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bers of the neurohypophysial peptide hormone receptor family
share certain sequence motifs and exhibit related pharmacolo-
gies (6–8). The hormone binding site of these receptors
includes residues from the TM bundle (9, 10), ECL1 (11–13),
and the N terminus (14–16).
Overall, the roles of residues locatedwithin the ECL domains
of GPCRs are not well understood compared with residues in
theTMdomain.Nevertheless, extracellular residues are impor-
tant for binding amine (17) and peptide ligands (18), binding
allosteric modulators (19), human immunodeficiency virus co-
receptor activity (20), switching agonist/antagonist properties
(21), and modulating agonist-induced receptor internalization
(22). For GPCRs in general, interest in the extracellular
domains has focused on ECL2 in particular, because it projects
into the binding crevice and there is direct evidence that its
conformation changes upon receptor activation (23). The aim
of this investigation was to provide a comprehensive pharma-
cological characterization defining the role of all the individual
residues comprising the entire ECL2 domain of a peptide-
GPCR. Systematic substitution of the V1aR by Ala generated a
series of mutant receptors that were subsequently analyzed
with respect to ligand binding (agonist/antagonist and peptide/
non-peptide) and intracellular signaling. Our results establish
that key residues located in ECL2 of the V1aR are required for
normal receptor function, identifying Phe189, Asp204, Cys205,
Trp206, Phe209, and Tyr218 as essential for high affinity agonist
binding and receptor activation.
EXPERIMENTAL PROCEDURES
Materials—AVPwaspurchased fromSigma.The cyclic peptide
antagonist (CA) 1-(-mercapto-,-cyclopentamethylenepropi-
onic acid), 2-(O-methyl)tyrosine AVP (d(CH2)5Tyr(Me)2AVP)
and linear peptide antagonist (LA) phenylacetyl-D-Tyr(Me)2
Arg6Tyr(NH2)9AVP were from Bachem (St. Helens, UK). SR
49059 was a gift from Sanofi Recherche (Toulouse, France).
Cell culture media, buffers, and supplements were pur-
chased from Invitrogen (Uxbridge, UK). Restriction enzymes
DpnI, HindIII, KpnI, and EcoR1 were from New England
Biolabs (Hitchin, UK) and Psp14601 was obtained fromMBI
Fermentas (Sunderland, UK).
Mutant Receptor Constructs—Mutation of the V1aR was
made using a PCR approach as described previously (24). The
mutant receptor constructs [F189A]V1aR, [S190A]V1aR,
[V191A]V1aR, [I192A]V1aR, [I194A]V1aR, [V196A]V1aR,
[N197A]V1aR, [G199A]V1aR, [T200A]V1aR, [K201A]V1aR,
[T202A]V1aR, [Q203A]V1aR, [C205A]V1aR, [W206A]V1aR,
[A207G]V1aR, [T208A]V1aR, [F209A]V1aR, [I210A]V1aR, and
[Q211A]V1aR were engineered using the antisense oligonu-
cleotides: 5-GGC-GCG-GGT-ACC-CCA-GGG-CTG-GAT-
GAA-CG-TTG-CCC-AGC-AGT-CTT-GGG-TTT-TAG-TG-
C-CAT-TGT-TCA-CCT-CGA-TTT-CGA-TCA-CAG-AGG-
CTA-TAA-AGT-ACT-GTG-G-3, 5-GGC-GCG-GGT-ACC-
CCA-GGG-CTG-GAT-GAA-CGT-TGC-CCA-GCA-GTC-
TTG-GGT-TTT-AGT-GCC-ATT-GTT-CAC-CTC-GAT-
TTC-GAT-CAC-AGC-GAA-TAT-AAA-GTA-CTG-TGG-3,
5-GGC-GCG-GGT-ACC-CCA-GGG-CTG-GAT-GAA-CG-
T-TGC-CCA-GCA-GTC-TTG-GGT-TTT-AGT-GCC-ATT-
GTT-CAC-CTC-GAT-TTC-GAT-CGC-AGA-GAA-TAT-A-
AA-GTA-CTG-TGG-3, 5-GGC-GCG-GGT-ACC-CCA-G-
GG-CTG-GAT-GAA-CGT-TGC-CCA-GCA-GTC-TTG-GG-
T-TTT-AGT-GCC-ATT-GTT-CAC-CTC-GAT-TTC-GGC-
CAC-AGA-GAA-TAT-AAA-GTA-CTG-TGG-3, 5-GGC-
GCG-GGT-ACC-CCA-GGG-CTG-GAT-GAA-CGT-TGC-C-
CA-GCA-GTC-TTG-GGT-TTT-AGT-GCC-ATT-GTT-CA-
C-CTC-GGC-TTC-GAT-ACA-GAG-3, 5-GGC-GCG-GG-
T-ACC-CCA-GGG-CTG-GAT-GAA-CGT-TGC-CCA-GCA-
GTC-TTG-GGT-TTT-AGT-CCC-ATT-GTT-CGC-CTC-G-
AT-TTCG-3, 5-GGC-GCG-GGT-ACC-CCA-GGG-CTG-
GAT-GAA-CGT-TGC-CCA-GCA-GTC-TTG-GGT-TTT-A-
GT-GCC-ATT-GGC-ACC-TCG-ATT-TCG-3, 5-GGC-GC-
G-GGT-ACC-CCA-GGG-CTG-GAT-GAA-CGT-TCC-AGC-
AGT-CTT-GGG-TTT-TAG-TGG-CAT-TGT-TCA-CC-3,
5-GGC-GCG-GGT-ACC-CCA-GGG-CTG-GAT-GAA-CG-
T-TGC-CCA-GCA-GTC-TTG-GGT-TTT-AGC-GCC-ATT-
GTT-CAC-C-3, 5-GGC-GCG-GGT-ACC-CCA-GGG-CT-
G-GAT-GAA-CGT-TGC-CCA-GCA-GTC-TTG-GGT-TGC-
AGT-GCC-ATT-G-3, 5-GGC-GCG-GGT-ACC-CCA-GG-
G-CTG-GAT-GAA-CGT-TGC-CCA-GCA-GTC-TTG-GGC-
TTT-AGT-GCC-3, 5-GGC-GCG-GGT-ACC-CCA-GGG-
CTG-GAT-GAA-CGT-TGC-CCA-GCA-GTC-TGC-GGT-T-
TT-AGT-GC-3, 5-GGC-GCG-GGT-ACC-CCA-GGG-CT-
G-GAT-GAA-CCG-TTG-CCC-AGG-CGT-CTT-GGG-3, 5-
GGC-GCG-GGT-ACC-CCA-GGG-CTG-GAT-GAA-CGT-
TGC-CGC-GCA-GTC-TTG-GG-3, 5-GGC-GCG-GGT-A-
CC-CCA-GGG-CTG-GAT-GAA-CGT-TCC-CCA-GCA-
GTC-3, 5-GGC-GCG-GGT-ACC-CCA-GGG-CTG-GAT-
GAA-CGC-TGC-CCA-GC-3, 5-GGC-GCG-GGT-ACC-C-
CA-GGG-CTG-GAT-GGC-CGT-TGC-CCA-GC-3, 5-GGC-
GCG-GGT-ACC-CCA-GGG-CTG-GGC-GAA-CGT-TGC-
CCA-GC-3, and 5-GGC-GCG-GGT-ACC-CCA-GGG-CGC-
GAT-GAA-CGT-TGC-CCA-GC-3, respectively. Each primer
contained base changes for the Ala mutation (shown in bold)
plus base changes to create a silent Psp1406I restriction site for
diagnostic purposes where possible (shown in italics, with base
changes in bold) and a uniqueKpnI restriction site (underlined)
for subcloning. The sense primer was 5-CGA-CTC-ACT-AT-
A-GGG-AGA-CCC-AAG-CTT-3 which contained a HindIII
site (underlined) for subcloning. The constructs [P212A]V1aR,
[W213A]V1aR, [G214A]V1aR, [T215]V1aR, [R216A]V1aR,
[A217G]V1aR, and [Y218A]V1aR were engineered using the
QuikChange site-directed mutagenesis kit (Stratagene, Cam-
bridge, UK) following the manufacturer’s instructions. The
antisense primers were: 5-CGG-GTA-CGC-CAG-GCC-TGG-
ATG-AAC-G-3, 5-GCG-CGT-ACC-GGC-GGG-CTG-GAT-
GAA-CG-3, 5-GGC-GCG-GGT-AGC-CCA-GGG-CTG-G-3,
5-CAC-GTA-GGC-GCG-GGC-AGC-CCA-GGG-C-3, 5-
GGT-CAC-GTA-GGC-GGC-CGT-ACC-C-3, 5-GGT-CAC-
GTA-GCC-GCG-CGT-ACC-C-3, and 5-GGT-CAT-CCA-G-
GT-CAC-GGC-GGC-GCG-GGT-CCC-CC-3 respectively.
The primers contained base changes (in bold) to incorporate
point mutations and to ablate a KpnI site (underlined, base
change in bold) for screening mutants. The sense primers
were complementary to the antisense primers cited above.
All receptor constructs were confirmed by automated fluo-
rescent sequencing (University of Birmingham, Birming-
ham, UK).
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Cell Culture and Transfection—HEK 293T cells were rou-
tinely cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% (v/v) fetal calf serum in humidified 5% (v/v)
CO2 in air at 37 °C. Cells were seeded at a density of5 105
cells/100-mm dish and transfected after 48 h using a calcium
phosphate precipitation protocol with 10g of DNA/dish (10).
RadioligandBindingAssays—Awashed cellmembrane prep-
aration of HEK 293T cells, transfected with the appropriate
receptor construct, was prepared as previously described (24),
and the protein concentration was determined using the BCA
protein assay kit (Pierce) using bovine serum albumin as stand-
ard. Radioligand binding assays were performed as previously
described (25) using either the natural agonist [Phe3-3,4,5-
3H]AVP (0.5–1.5 nM), (64.2 Ci/mmol, PerkinElmer Life Sci-
ences), or the V1aR-selective peptide antagonist phenylacetyl-D-
Tyr(Me)2Arg6(3,43H-Pro)(3,53H-Tyr)9NH2-AVP (0.5–1.0 nM),
(22 Ci/mmol, custom synthesis Pheonix Pharmaceuticals, Inc.,
Belmont, CA) (26) as tracer ligand. Binding data were analyzed
by non-linear regression to fit theoretical Langmuir binding
isotherms to the experimental data using Prism (GraphPad, San
Diego, CA). Individual IC50 values obtained for competing
ligands were corrected for radioligand occupancy as described
(27) using the radioligand affinity (Kd) experimentally deter-
mined for each construct.
Determination of Cell-surface Expression Using Enzyme-
linked Immunosorbent Assay—All receptor constructs incor-
porated an hemagglutinin epitope tag in the N terminus, which
enabled cell-surface expression to be determined by enzyme-
linked immunosorbent assay as described previously (28).
Results were normalized against a wild-type control processed
in parallel. Non-transfected cells were used to determine back-
ground. All experiments were performed in quadruplicate.
AVP-induced Inositol Phosphates Production—HEK 293T
cells were seeded at a density of 2.5 105 cells/well in poly-D-
lysine-coated 12-well plates and transfected after 24 h using
TransfastTM (Promega, Madison, WI). AVP-induced accumu-
lation of inositol phosphates (InsPs) was assayed as described
previously (29). Briefly, following prelabeling of transfected
cells with 2 Ci/ml myo-[2-3H]inositol (22.0 Ci/mmol,
PerkinElmer Life Sciences) in inositol-freeDulbecco’smodified
Eagle’s medium containing 1% (v/v) fetal calf serum, a mixed
fraction containing mono-, bis-, and trisphosphates (InsP-
InsP3) was collected following stimulation by AVP, at the con-
centrations indicated, in the presence of 10 mM LiCl.
RESULTS
Functional Importance of Individual Residues in ECL2 of
the V1aR—The individual residues comprising ECL2 of the
V1aR, plus the residues at the extracellular boundary of
TMV, are presented in Fig. 1. Overall, this segment of the
extracellular face of the V1aR encompassed 30 residues, from
Phe189 to Tyr218 inclusive. To assess the importance of these
residues in V1aR function, each residue was substituted indi-
vidually by Ala (Ala207 and Ala217 were substituted by Gly)
and then pharmacologically characterized using the natural
agonist AVP and three structural classes of antagonist: (i)
cyclic peptide antagonist (CA), [d(CH2)5Tyr(Me)2]AVP, (30);
(ii) linear peptide antagonist (LA), [phenylacetyl-D-
Tyr(Me)2Arg6Tyr(NH2)9]AVP); and (iii), nonpeptide antago-
nist (SR 49059) (31). The Kd values are presented in Table 1,
corrected for radioligand occupancy. The majority of mutant
receptors exhibited wild-type pharmacology. Consequently,
[S190A]V1aR, [V191A]V1aR, [I192A]V1aR, [E193A]V1aR,
[I194A]V1aR, [E195A]V1aR, [V196A]V1aR, [N197A]V1aR,
[G199A]V1aR, [T200A]V1aR, [K201A]V1aR, [T202A]V1aR,
[Q203A]V1aR, [A207G]V1aR, [T208A]V1aR, [I210A]V1aR,
[Q211A]V1aR, [P212A]V1aR, [W213A]V1aR, [G214A]V1aR,
[T215A]V1aR, [R216A]V1aR, and [A217G]V1aR had only a
slight effect on the binding of the agonist AVP and the three
different classes of antagonist (Table 1), indicating that the
receptor protein was folded appropriately. The wild-type V1aR
and these mutant receptors were all expressed at the same level
of 1–2 pmol/mg of protein. Furthermore, the intracellular sig-
naling capability of these mutants was also essentially wild type
(Table 2), consistentwith thewild-type ligand binding profile of
these receptor constructs.
In marked contrast, [F189A]V1aR, [C205A]V1aR, [W206A]
V1aR, [F209A]V1aR, and [Y218A]V1aR exhibited severely
impaired agonist binding, with AVP affinity decreasing2000-
fold for [W206A]V1aR, [Y218A]V1aR, and 200-fold for
[F209A]V1aR, compared with wild type (Fig. 2). The affinity of
the three classes of antagonist remained essentially wild type
for [W206A]V1aR and [F209A]V1aR (Table 1), indicating that
the mutant receptor proteins were folded appropriately. It was
noted, however, that the affinity of CA for [F209A]V1aR was
decreased 8-fold relative to wild type (Table 1). It should be
noted that we recently reported in a separate study (28) that
substitution of Asp204 by Ala disrupted agonist binding and
intracellular signaling. Consequently, these data will not be dis-
cussed in detail here; however, data for [D204A]V1aR are cited
FIGURE 1. Schematic diagram of ECL2 of the V1aR. The tops of TMIII–TMV
are shown as dark gray cylinders and numbered accordingly. Residues inves-
tigated in this study are shown aswhite circles. The Cys (light gray circle) at the
top of TMIII is not part of this study and is included to show the position of the
conserved disulfide bond (black line) between ECL2 and TMIII. The branched
structure indicates an N-glycosylation site previously shown experimentally
to be utilized (42).
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in Table 1 to provide a complete study. In addition to the
marked decrease in AVP affinity noted above, [Y218A]V1aR
also had decreased affinity compared with wild type, for CA
(2000-fold) and SR49059 (50-fold). However, LA binding to
[Y218A]V1aR was essentially wild type. The LA binding indi-
cated that the overall fold of the receptor was appropriate and,
furthermore, allowed quantification of ligand binding affinities
to [Y218A]V1aR using [3H]LA as tracer (Table 1). Because nei-
ther of the radioligands available bound to [F189A]V1aR nor
[C205A]V1aR within the practical concentration range for
ligand binding assays, it was not possible to quantify the
decrease in ligand affinity at these mutant receptors.
Role of Key Individual Residues in ECL2 of the V1aR in Intra-
cellular Signaling—Assaying AVP-induced accumulation of
InsP-InsP3 revealed that the ECL2 mutants [F189A]V1aR,
[C205A]V1aR, [W206A]V1aR, [F209A]V1aR, and [Y218A]V1aR
all exhibited impaired intracellular signaling (Table 2), with the
degree of perturbation being dependent on the locus of the
mutation (Fig. 3). The severity of the impaired signaling could
be divided into three groups: (i) [W206A]V1aR, [F209A]V1aR,
and [Y218A]V1aR had EC50 values for AVP-induced accumula-
tion of InsP-InsP3 20-fold, 14-fold, and 39-fold, respectively,
greater thanwild-typeV1aR; (ii) [F189A]V1aR exhibited anEC50
value 150-fold greater than wild-type V1aR; and (iii)
[C205A]V1aR was incapable of initiating a InsP-InsP3 response
when challenged by a high AVP concentration (1 M). None of
the mutant receptors displayed constitutive activity.
Given that the mutant receptors [F189A]V1aR, [C205A]
V1aR, [W206A]V1aR, [F209A]V1aR, and [Y218A]V1aR had
impaired ligand binding and intracellular signaling, cell-surface
expression of these constructs was determined (Fig. 4). Cell-sur-
face expression of [W206A]V1aR was wild type, whereas the sur-
face expression of [F189A]V1aR, [F209A]V1aR, and [Y218A]V1aR
was 60–80%ofwild type. The surface expression of [C205A]V1aR
was only 40% ofwild-type andwas the lowest of all the engineered
constructs.
DISCUSSION
The ECL2 domain of bRho forms a -hairpin that plunges
down into the TM bundle, forming a lid over the bound retinal,
which shields it from the extracellular milieu. This protein fold
positions residues in the second -strand (4) of this ECL2
hairpin structure in close proximity to the chromophore. Con-
sequently, Glu181, Gly188, Ile189, and Tyr191 of bRho all make
contact with retinal (1). Given the unusual nature of the
TABLE 1
Pharmacological profile of ECL2 mutant V1aRs
Mutant V1aRs were expressed in HEK 293T cells and characterized pharmacologi-
cally. Dissociation constants (Kd) were calculated from IC50 values and corrected for
radioligand occupancy as described under Experimental Procedures. Data shown
are themean S.E. (n 3) of three replicates. CA cyclic peptide antagonist, LA
linear peptide antagonist, SR 49059 nonpeptide antagonist.
Receptor Binding affinities, KdAVP CA LA SR 49059
nM
Wild-type V1aR 1.0 0.1 0.7 0.3 0.5 0.1 1.9 0.3
F189A No binding No binding
S190A 2.75 1.01 1.95 0.77 0.28 0.06 1.98 0.46
V191A 1.91 0.91 1.61 0.36 0.22 0.03 1.35 0.13
I192A 2.51 0.35 2.50 0.74 1.10 0.68 2.84 0.86
E193Aa 1.53 0.21 0.93 0.25 1.02 0.10 0.28 0.02
I194A 0.75 0.44 1.55 0.18 1.55 0.18 1.40 0.45
E195Aa 0.89 0.03 0.63 0.08 0.18 0.10 3.39 0.54
V196A 2.20 0.48 1.28 0.42 1.07 0.31 1.61 0.49
N197A 2.06 0.38 1.84 0.35 2.24 0.59 3.28 0.71
N198Qb 0.90 0.10 0.50 0.10 0.50 0.10 1.60 0.20
G199A 1.85 0.43 2.64 0.44 0.50 0.08 2.50 1.30
T200A 2.34 0.40 0.55 0.26 2.37 1.29 1.48 0.62
K201A 1.42 0.32 0.44 0.36 0.70 0.30 1.35 0.27
T202A 1.76 0.08 1.72 0.19 2.00 0.96 2.53 0.52
Q203A 1.67 0.33 1.89 0.44 1.51 0.54 2.26 0.84
D204Aa 2300 240 2.00 0.4 10.0 3.4 1.3 1.2
C205A No binding No binding
W206A 1431 344 2.03 0.51 0.32 0.06 1.04 0.26
A207G 1.64 0.11 1.20 0.35 0.45 0.13 1.05 0.05
T208A 1.09 0.17 1.85 0.30 0.70 0.12 1.84 0.16
F209A 212 72 5.90 1.13 0.10 0.02 1.22 0.21
I210A 1.30 0.12 1.62 0.59 1.76 0.69 2.48 0.28
Q211A 1.95 0.28 0.94 0.15 0.88 0.32 1.47 0.31
P212A 1.03 0.36 0.75 0.07 0.93 0.31 1.16 0.21
W213A 1.92 0.86 2.18 0.40 0.92 0.23 2.96 1.51
G214A 1.50 0.09 1.16 0.28 0.29 0.06 1.33 0.41
T215A 0.92 0.28 0.70 0.16 0.51 0.09 1.84 0.52
R216Aa 0.80 0.13 0.44 0.05 0.46 0.10 0.93 0.17
A217G 2.49 0.30 2.24 0.06 1.64 0.30 3.99 1.05
Y218A 1954 525 1478 357 0.93 0.20 96.1 20.8
aData from Ref. 28.
bData from Ref. 42.
TABLE 2
Intracellular signaling by ECL2mutant V1aRs
EC50 and Emax values of AVP-induced accumulation of InsP-InsP3 in cells express-
ing wild-type (WT) andmutant receptors are shown. Values shown are themean
S.E. of three separate experiments performed in triplicate. Basal values (mean 
S.E.) were 1228 146, 1064 93, 1197 139, 1043 28, 1346 135, 891 170,
1053 115, 1009 188, 929 187, 1219 74, 1043 25, 1213 255, 911 24,
1250 143, 893 93, 1554 279, 973 146, 1073 100, 788 239, 1213 240,
860  23, 969  59, 1246  14, 1246  14, 1684  347, 1128  203, 831  132,
1154  153, 953  186, 1083  162, and 864  11 dpm for wild-type V1aR,
F189AV1aR, S190AV1aR, V191AV1aR, I192AV1aR, E193AV1aR,
I194AV1aR, E195AV1aR, V196AV1aR, N197AV1aR, N198QV1aR,
G199AV1aR, T200AV1aR, K201AV1aR, T202AV1aR, Q203AV1aR,
D204AV1aR, C205AV1aR, W206AV1aR, A207GV1aR, T208AV1aR,
F209AV1aR, I210AV1aR, Q211AV1aR, P212AV1aR, W213AV1aR,
G214AV1aR, T215V1aR, R216AV1aR, A217GV1aR, and Y218AV1aR, respec-
tively. None of the mutant receptors displayed constitutive activity.
Receptor construct AVP-induced IP-IP3 accumulationEC50 Emax
nM -Fold
Wild-type V1aR 1.18 0.16 5.52 0.26
F189A 146.89 14.02 1.71 0.04
S190A 2.39 0.40 6.11 1.03
V191A 2.49 1.07 7.12 0.43
I192A 1.45 0.08 5.16 1.43
E193A 0.30 0.12 4.98 0.12
I194A 3.20 1.39 5.64 1.23
E195A 1.01 0.13 7.88 0.65
V196A 1.05 0.17 4.60 1.10
N197A 1.16 0.05 6.51 0.52
G199A 1.14 0.62 3.98 0.02
T200A 1.55 0.52 3.92 0.92
K201A 1.56 0.32 7.95 0.16
T202A 1.56 0.32 4.72 0.19
Q203A 1.18 0.11 7.26 1.47
D204A 7.00 1.30 4.80 0.50
C205A NSa NS
W206A 20.24 7.57 4.56 0.56
A207G 0.83 0.12 9.88 3.76
T208A 1.40 0.38 5.85 2.30
F209A 13.75 5.83 6.21 0.86
I210A 0.87 0.13 7.17 0.96
Q211A 0.46 0.22 5.18 0.59
P212A 1.41 0.38 3.47 1.12
W213A 1.51 0.18 5.84 1.67
G214A 1.16 0.34 6.75 1.36
T215A 0.57 0.37 6.72 1.69
R216A 0.30 0.03 6.46 0.12
A217G 0.88 0.26 7.23 2.02
Y218A 39.31 10.54 7.24 1.08
aNS, no stimulation.
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covalently bound ligand in bRho, the variation in sequence and
length of ECL2 within Family A GPCRs, and the requirement
for reversible ligand access from the extracellular medium, it is
perhaps possible that this -hairpin fold is a unique feature of
opsins. Indeed, the two-dimensional nuclear magnetic reso-
nance structure of some synthetic ECL2 peptides has resulted
inGPCRmodels that incorporate a different conformation. For
example, it has been proposed that ECL2 of the thromboxane
A2 receptor contains two -turns and extends away from the
TM bundle (32). Alternatively, a helical conformation preced-
ing the conserved Cys, or central to the ECL2 loop, was sug-
gested for the -opioid receptor (33) and the neurokinin-1
receptor (34, 35), respectively. However, using the substituted-
cysteine accessibility method to identify residues contributing
FIGURE 2. Pharmacological characterization of ECL2 mutant receptors.
Radioligand binding assays were performed using a membrane preparation
of HEK 293T cells transiently transfected with either: wild-type V1aR (E),
[W206A]V1aR (F), [F209A]V1aR (), and [Y218A]V1aR (f) with the competing
ligand being AVP (A), CA (B), or SR49059 (C). Data are themean S.E. of three
separate experiments each performed in triplicate using [3H]AVP (0.5–1.5 nM)
or [3H]LA (0.5–1.0 nM) as tracer. Values are expressed as percent specific bind-
ing where nonspecific binding was defined by d(CH2)5Tyr(Me)
2AVP (1 M) or
LA (1 M). A theoretical Langmuir binding isotherm has been fitted to the
experimental data as described under “Experimental Procedures.”
FIGURE 3. Intracellular signaling by ECL2mutant receptors. AVP-induced
accumulation of inositol mono-, bis-, and trisphosphates in HEK 293T cells
transiently transfectedwith: wild-type V1aR (E), [F189A]V1aR (Œ), [C205A]V1aR
(), [W206A]V1aR (F), [F209A]V1aR (»), and [Y218A]V1aR (f). Data are the
mean S.E. of three separate experiments each performed in triplicate. Val-
ues are stimulation inducedbyAVP at the stated concentrations expressed as
percent maximum.
FIGURE 4. Cell-surface expression of ECL2 mutant receptors. The cell-sur-
face expression of mutant receptors was determined by enzyme-linked
immunosorbent assay as described in “Experimental Procedures.” Results
were normalized against awild-type control processed in parallel. Non-trans-
fected cells were used to determine background. All experiments were per-
formed three times in triplicate.
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to the water-accessible binding site crevice of the D2 dopamine
receptor (D2R), Shi and Javitch concluded that the ECL2 loop of
the D2R adopted a similar conformation as the corresponding
loop in bRho (4). In addition, this conclusion is consistent with
ECL2 site-directedmutagenesis data for other Family AGPCRs
(reviewed in Ref. 17).
The aim of this study was to systematically define the role of
the individual residues that comprise the ECL2 domain of the
V1aR. The majority of these mutant receptor constructs, 24 in
total, had essentially wild-type ligand binding and intracellular
signaling characteristics, indicating that these residues were
not important for normal receptor function. In contrast, sub-
stitution of Cys205 ablated both ligand binding and signaling.
This Cys is part of the disulfide bond between ECL2 and the top
of TMIII (Cys3.25),6 which is conserved in nearly all Family A
GPCRs, and contributes to structural integrity of the receptor.
Consistent with this structural role, cell-surface expression of
[C205A]V1aR was only 40% of wild type. Receptor function was
also disrupted when the corresponding Cys was mutated in
bRho (36),M3muscarinic acetylcholine receptor (37),2-adre-
nergic receptor (2-AR) (38), NK1 receptor (39), and the gona-
dotropin-releasing hormone receptor (40).
There are a total of five aromatic residues within the extra-
cellular segment of the V1aR investigated in this study, Phe189,
Trp206, Phe209, Trp213, and Tyr218. All five residues are highly
conserved throughout members of the vertebrate neurohy-
pophysial hormone sub-family ofGPCRs cloned to date (Fig. 5).
Furthermore, residues Trp206, Phe209, Trp213, and Tyr218 are
part of a sequence motif, DCWAXFXXPWGX(R/K)AY, which
is highly conserved throughout this sub-family of GPCRs but is
not a feature of FamilyAGPCRs in general. This family-specific
conservation, plus the extracellular location of the motif in the
receptor architecture, led to the hypothesis that residues in this
motif may be candidates for ligand recognition (5, 41). Consist-
ent with this hypothesis, we show in the current study that
mutation of the aromatic residues Trp206, Phe209, or Tyr218
(shown underlined in the motif DCWAXFXXPWGX(R/K)AY)
resulted in decreased affinity for agonist (Table 1) and impaired
intracellular signaling (Table 2). This loss of AVP binding was
not due to gross aberrant assembly of the mutant receptors,
because the binding of at least one antagonist was wild type.
Disruption of receptor function was not due to poor expression
of the mutant receptors, because cell-surface expression of
[W206A]V1aR, [F209A]V1aR, and [Y218A]V1aR was 60–100%
of wild type (Fig. 4), and we have shown previously that a
mutant receptor expressed at only 50%ofwild-typeV1aR exhib-
ited wild-type signaling (28). In common with Trp206, Phe209,
and Tyr218, the residue Trp213 is also part of the DCWAXFXX-
PWGX(R/K)AY motif (shown underlined) and is highly con-
served in neurohypophysial hormone receptors cloned to date,
with the single exception of the vasotocin receptor from bull
frog, in which Lys replaces the Trp. However, despite this high
degree of conservation, Trp213 is not important for receptor
function, because [W213A]V1aR exhibited essentiallywild-type
ligand binding and signaling.
Conserved residues within the TM bundle were used to
establish a universal residue nomenclature system (43). It is
difficult to directly compare ECL2 residues from different
GPCRs, because there is a lack of sequence conservation and
the loop length varies between receptors. However, ECL2 con-
tains a highly conserved Cys, which is one half of the disulfide
bond conserved in the majority of Family A GPCRs. This disul-
fide bond will spatially constrain relative movement between
ECL2 and TMIII and therefore provide a point of reference for
comparison between differentGPCRs.Wepropose an indexing
method for comparing aligned ECL2 residues in different
GPCRs in which the conserved Cys is the reference point and
other residues are indexed relative to this position. For exam-
ple, for the rat V1aR (Fig. 5), the residue preceding the con-
served Cys is Asp(C	1) and the residue following the Cys is
Trp(C
1).
Trp206(C
1) and Phe209(C
4) in the V1aR correspond to
Gly188(C
1) and Tyr191(C
4) in bRho. In the bRho crystal struc-
ture, Gly188(C
1) and Tyr191(C
4) are in the 4 strand of the
ECL2 hairpin and come within 5 Å of the retinal to form part of
the chromophore binding pocket (1, 44). Consequently, assum-
ing that the tertiary fold of ECL2 in the V1aR is similar to that of
ECL2 in bRho, then Trp206(C
1) and Phe209(C
4) will be
6 Residues in the TMs are referred to by residue number and the nomencla-
ture of Ballesteros and Weinstein (43).
FIGURE 5. Comparison of the ECL2 sequence of neurohypophysial hor-
mone receptors cloned fromdifferent species. The sequences of the ECL2
domain of the V1aR, V1bR, V2R, and OTR from different species have been
aligned. The species of origin is indicated by a single letter code preceding the
receptor subtype: r, rat; m, mouse; v, vole; s, sheep; h, human; p, pig; b, cow;
d, dog;mk, rhesusmonkey. ECL2 residues that are highly conserved through-
out the neurohypophysial hormone receptor family are shown in bold. The
highly conserved aromatic residues within ECL2, shown to be functionally
important in this study, are boxed and numbered according to the rV1aR
sequence. Sequences citedwere obtained fromSwissProt andGenEMBL. The
Cys in ECL2 which forms part of the disulfide bond conserved in Family A
GPCRs is indicated by an asterisk.
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directed down into the binding cavity within the helical bundle.
Such an orientation of these residues would be entirely consist-
entwith the disruption of ligandbinding and signaling observed
for [W206A]V1aR and [F209A]V1aR. It is noteworthy that C
1
and C
4 residues in this “4 strand segment” of ECL2 can also
be important for ligand binding to amine-GPCRs. Indeed,
Phe209(C
4) is part of the Cys-X-X-X-Ar motif (where Ar is an
aromatic residue) that is well conserved in both peptide-GPCRs
(59%) and amine-GPCRs (17%). In addition, Gln189(C
1) of the
5-HT1D receptor, corresponding to Trp206(C
1) of the V1aR,
contributes to the subtype selectivity of ketanserin (45), and
Gln177(C
1) is part of a triad of ECL2 residues responsible for
1AAR versus 1BAR pharmacology (46). In peptide-GPCRs,
Arg197(C
1) of the cholecystokinin-1 receptor makes direct
contact with Tyr(SO4)2 of cholecystokinin (47) andmutation of
Tyr190(C
4) in the CXCR4 chemokine receptor, resulted in
impaired signaling (48).
Tyr218(5.38) at the extracellular boundary of TMV is abso-
lutely conserved throughout the neurohypophysial peptide
hormone receptor sub-family of GPCRs and is part of the same
conserved sequence motif (DCWAXFXXPWGX(R/K)AY,
shown underlined) as Trp206(C
1) and Phe209(C
4).Mutation of
Tyr218(5.38) in the construct [Y218A]V1aR disrupted both ligand
binding and intracellular signaling suggesting that Tyr218(5.38) is
orientated into the ligand binding site. For the D2R, it has been
shown that the corresponding residue Phe5.38 points into the
binding site crevice by using a substituted-cysteine accessibility
method in conjunction with ligand protection (49). Likewise,
mutation of Tyr5.38 of the 1B-adrenergic receptor also dis-
rupted agonist binding and signaling (50). Our conclusion that
Tyr218(5.38) orientates into the ligand binding crevice also pro-
vides a feasible mechanism for the naturally occurring “loss-of-
function” mutation Y205C in the human V2R (equivalent to
Tyr218 in the V1aR), which has been identified as a cause of
nephrogenic diabetes insipidus in some families (51).
The conserved residues in ECL2 corresponding to Val196(C	9)
plus Ala211(C
2), Pro212(C
7), Gly214(C
9), Arg216(C
11), and
Ala217(C
12) (shown underlined in DCWAXFXXPWGX(R/K)AY)
are present in all vertebrate AVP/OT receptors cloned to date
(Fig. 5), with the exception of only the rodent V1bR (Pro(C
7)3
Ser), the sheep V1aR (Arg(C
11) 3 Pro), and the human V2R
(Ala(C
12) 3 Thr). Nevertheless, the mutant receptors
[V196A]V1aR, [A211G]V1aR, [P212A]V1aR, [G214A]V1aR,
[R216A]V1aR, and [A217G]V1aR were all near wild type with
respect to binding agonist, three different classes of antagonist
and intracellular signaling capability. Consequently, despite
comprising a large part of a “signature motif” throughout the
AVP/OT receptor family, these conserved ECL2 residues do
not seem to have a role in receptor function.
Phe189 at the start of ECL2 is highly conserved throughout
the neurohypophysial peptide hormone receptor family with
the single exception of the cephalotocin receptor, found in
octopus, where a Trp replaces the conserved Phe. This high
level of conservation reflects functional importance, because
[F189A]V1aR exhibited a dramatic decrease in potency (150-
fold) of AVP-induced InsP signaling and severely disrupted
ligand binding. The corresponding residue (Trp175) in bRho
packs against Phe203 at the top of TMV (corresponding to
Tyr218 in the V1aR) (52). It is likely that this interaction between
the extreme ends of ECL2 is important for the orientation/
stability of the ECL2 cap over the binding pocket, because both
[F189A]V1aR and [Y218A]V1aR possessed disrupted ligand
binding and signaling (this study) and [W175A]bRho exhibited
impaired regeneration of the dark photoreceptive state follow-
ing photoactivation (53). Although it is clear that the ECL2
domain can fulfill a range of functions in GPCRs in general, the
details of its role are receptor-specific. Random saturation
mutagenesis of ECL2 in the C5a receptor (C5aR) identified
multiple mutations exhibiting constitutive activity, suggesting
that in thewild-type receptor ECL2 stabilized the inactiveC5aR
(54). Likewise, for another glycoprotein-GPCR, the thyroid-
stimulating hormone receptor, it has been reported that an
interaction betweenECL2 andTMVI constrains the receptor in
an inactive state. Consequently, substitution of Ile568 in ECL2of
the thyroid-stimulating hormone receptor by a range of diverse
residues (including the pathogenic mutant I568V) generates
constitutive activity (55). In contrast, random mutagenesis of
theM3muscarinic acetylcholine receptor (M3R) identified sev-
eral ECL2 residues important for stabilizing the active state of
the M3R mAChR and furthermore, established that ECL2 res-
idues were not important for agonist binding to M3R (56). In
the current study, we have established that key residues pro-
vided by ECL2 of a small peptide-GPCR are important for ago-
nist binding and receptor activation. Consequently, ECL2 is
important for normal function of theC5aR,M3R, andV1aR, but
the role fulfilled by ECL2 is different for each of these receptors.
These differences in the role of ECL2 probably reflect differ-
ences in the binding mode between large peptide ligand, amine
ligand, and small peptide ligand, respectively.
The side chain of Asn198 is not available for inter-molecular
or intra-molecular contacts, because it is modified by N-linked
glycosylation. The carbohydrate is not required for ligand bind-
ing or intracellular signaling but does have a role in cell-surface
expression (42). This post-translational modification has to be
accommodated within the tertiary structure of ECL2. If ECL2
forms a plunging -hairpin in V1aR, similar to bRho, then the
oligosaccharide chainmust project from the helical bundle into
the extracellularmediumwithout steric clashes. Alternatively if
the ECL2 domain extends into the extracellular milieu, then
glycosylation of ECL2 may serve to stabilize this orientation.
Although ECL2 in bRho is not glycosylated, such modification
is not rare in GPCRs. Analyzing the sequences of 613 Family A
GPCRs revealed that 32% possess at least one consensusN-gly-
cosylation site (NX(S/T)) in ECL2. For the vastmajority of these
receptors (85%), the ECL2 N-glycosylation site is not located
within the sequence corresponding to the 4-strand of bRho,
i.e. not within the deeply buried -strand of the ECL2 hairpin,
thereby allowing the oligosaccharide to be accommodated
more easily within the tertiary structure.
In conclusion, we have shown that key residues located in
ECL2 of the V1aR are required for normal receptor function,
identifying Phe189, Asp204, Cys205, Trp206, Phe209, and Tyr218 as
essential for high affinity agonist binding and receptor activa-
tion. In addition, Tyr218 was also required for high affinity bind-
ing of CA and nonpeptide antagonist. Consistent with their
fundamental role in receptor function, these residues are highly
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conserved throughout the neurohypophysial hormone recep-
tor sub-family of GPCRs.
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